Department of Innovative Research & Education for Clinicians & Trainees (DiRECT)

英文原著 2017年度実績

  1. Omae K, Tsujimoto Y, Honda M, Kondo T, Tanabe K, Fukuhara S, Furukawa T.
    Comparative Efficacy and Safety of Bone-modifying Agents for the Treatment of Bone Metastases in Patients with Advanced Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
    Oncotarget  2017 18; 8: 68890-68898.
  2. Yokoyama K*, Kurita N*, Fukuma S, Akizawa T, Fukagawa M, Onishi Y, Kurokawa K, Fukuhara S. (*co-first authors)
    Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy.
    Nephrology Dialysis Transplantation 2017; 32: 534-541.
  3. Kurita N, Hayashino Y, Yamazaki S, Akizawa T, Akiba T, Saito A, Fukuhara S.
    Revisiting Interdialytic Weight Gain and Mortality Association With Serum Albumin Interactions: The Japanese Dialysis Outcomes and Practice Pattern Study.
    Journal of Renal Nutrition 2017; 27: 421-429.
  4. Omae K, Fukuma S, Ikenoue T, Kondo T, Takagi T, Ishihara H, Tanabe K, Fukuhara S
    Impact of ABO blood type on the outcomes of metastatic renal cell carcinoma patients treated with first-line tyrosine kinase inhibitors.
    Urologic Oncology 2017; 35: 540.e7-540.e12. 
  5. Miyamoto M, Kurita N, Suemitsu K, Murakami M.
    Fistula and survival outcomes after fistula creation among predialysis chronic kidney disease stage 5 patients.
    American Journal of Nephrology 2017; 45: 356-364.
  6. Omae K, Kondo T, Takagi T, Iizuka J, Hashimoto Y, Kobayashi H, Tanabe K.
    Surgical and Oncologic Outcomes of Laparoscopic Radical Nephrectomy for Non-metastatic Renal Cancer in Long-term Dialysis Patients.
    Ther Apher Dial. 2017; 21: 31-37.
  7. Kataoka Y, Yamamoto S, Omae K, Kokubo M, Goto Y, Takada T, Naganuma T, Nishiwaki H, Yajima N.
    A novel approach of understanding prediction models: TRIPOD framework.
    Journal of General and Family Medicine 2017; 18: 319-320.
  8. Ishihara H, Kondo T, Yoshida K, Omae K, Takagi T, Iizuka J, Tanabe K.
    Evaluation of preoperative aspartate transaminase/alanine transaminase ratio as an independent predictive biomarker in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy: A propensity score matching study.
    Clinical Genitourinary Cancer 2017; 15: 598-604.
  9. Ishihara H, Kondo T, Yoshida K, Omae K, Takagi T, Iizuka J, Tanabe K.
    Preoperative controlling nutritional status (CONUT) score as a novel predictive biomarker of survival in patients with localized urothelial carcinoma of the upper urinary tract treated with radical nephroureterectomy.
    Urologic Oncology 2017; 35: 539.e9-539.e16.
  10. Ishihara H, Kondo T, Yoshida K, Omae K, Takagi T, Iizuka J, Tanabe K.
    Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy.
    Urologic Oncology 2017; 35: 542.e1-542.e9.